These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 15002058

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B, Hoermann R, Hahn S, Roggenbuck U, Mann K, Janssen OE.
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [Abstract] [Full Text] [Related]

  • 3. Clinical value of M22-based assays for TSH-receptor antibody (TRAb) in the follow-up of antithyroid drug treated Graves' disease: comparison with the second generation human TRAb assay.
    Massart C, Gibassier J, d'Herbomez M.
    Clin Chim Acta; 2009 Sep; 407(1-2):62-6. PubMed ID: 19576193
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Improved prediction of relapse of Graves' thyrotoxicosis by combined determination of TSH receptor and thyroperoxidase antibodies.
    Schott M, Eckstein A, Willenberg HS, Nguyen TB, Morgenthaler NG, Scherbaum WA.
    Horm Metab Res; 2007 Jan; 39(1):56-61. PubMed ID: 17226115
    [Abstract] [Full Text] [Related]

  • 6. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B, Hoermann R, Roggenbuck U, Hahn S, Mann K, Janssen OE, Basedow Study Group.
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Changes in TSH receptor antibody levels (TRAb) as markers of effectiveness of various therapies in Graves-Basedow's disease.
    Bojarska-Szmygin A, Janicki K, Pietura R, Janicka L.
    Ann Univ Mariae Curie Sklodowska Med; 2003 Sep; 58(1):248-53. PubMed ID: 15314994
    [Abstract] [Full Text] [Related]

  • 12. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
    Carella C, Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, Nersita R, Iorio S, Amato G, Braverman LE, Roti E.
    Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
    [Abstract] [Full Text] [Related]

  • 13. Clinical value of the first automated TSH receptor autoantibody assay for the diagnosis of Graves' disease (GD): an international multicentre trial.
    Schott M, Hermsen D, Broecker-Preuss M, Casati M, Mas JC, Eckstein A, Gassner D, Golla R, Graeber C, van Helden J, Inomata K, Jarausch J, Kratzsch J, Miyazaki N, Moreno MA, Murakami T, Roth HJ, Stock W, Noh JY, Scherbaum WA, Mann K.
    Clin Endocrinol (Oxf); 2009 Oct; 71(4):566-73. PubMed ID: 19170704
    [Abstract] [Full Text] [Related]

  • 14. Graves' disease: evolution and prognosis after eight months of treatment with methimazole.
    Gauna AT, Guillén CE, Sartorio GC, Soto RJ.
    Medicina (B Aires); 1992 Oct; 52(3):207-12. PubMed ID: 1364158
    [Abstract] [Full Text] [Related]

  • 15. [Individual outcome monitoring of TSH receptor antibody level for predicting the prognosis of Graves' disease].
    Rink T, Holle LH, Schroth HJ, Garth H.
    Nuklearmedizin; 1998 May; 37(3):90-4. PubMed ID: 9604228
    [Abstract] [Full Text] [Related]

  • 16. TSH receptor antibodies for confirming the diagnosis and prediction of remission duration, in newly diagnosed Graves' disease patients.
    Aleksić A, Aleksić Z, Stojanović M.
    Hell J Nucl Med; 2009 May; 12(2):146-50. PubMed ID: 19675869
    [Abstract] [Full Text] [Related]

  • 17. On specificity of 2nd generation TSH receptor autoantibody measurements.
    Zöphel K, Grüning T, Roggenbuck D, Wunderlich G, Kotzerke J.
    Clin Lab; 2008 May; 54(7-8):243-9. PubMed ID: 18942492
    [Abstract] [Full Text] [Related]

  • 18. Thyrotropin Receptor Antibody Levels at Diagnosis and After Thionamide Course Predict Graves' Disease Relapse.
    Tun NN, Beckett G, Zammitt NN, Strachan MW, Seckl JR, Gibb FW.
    Thyroid; 2016 Aug; 26(8):1004-9. PubMed ID: 27266892
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of the 2nd generation radio-receptional assay for anti-TSH receptor antibodies (TRAb) in autoimmune thyroid diseases. Comparison with 1st generation and anti-thyroperoxidase antibodies (AbTPO).
    Giovanella L, Ceriani L, Garancini S.
    Q J Nucl Med; 2001 Mar; 45(1):115-9. PubMed ID: 11456370
    [Abstract] [Full Text] [Related]

  • 20. [Prospective study on the relationship between treatment duration of antithyroid drug and remission rate of Graves' disease].
    Liu C, Duan Y, Wu X.
    Zhonghua Yi Xue Za Zhi; 2000 Nov; 80(11):835-7. PubMed ID: 11218878
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.